Prevention of steroid-induced osteonecrosis of femoral head in systemic lupus erythematosus by anti-coagulant

Lupus

Volumn 15, Issue 6, 2006, Pages 354-357

  Nagasawa, Kohei ^a   Tada, Y ^a   Koarada, S ^a   Tsukamoto, H ^b   Horiuchi, T ^b   Yoshizawa, S ^c   Murai, K ^d   Ueda, A ^e   Haruta, Y ^a   Ohta, A ^a  

^a SAGA UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c Munakata Medical Association Hospital   (Japan)

^d UNIVERSITY OF MIYAZAKI   (Japan)

^e MIYAZAKI PREFECTURAL MIYAZAKI HOSPITAL   (Japan)

Author keywords

Clinical trial; Corticosteroid; Osteonecrosis of femoral head; SLE; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; PREDNISOLONE; STEROID; WARFARIN;

ADOLESCENT; ADULT; ANTICOAGULANT THERAPY; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG EFFECT; FEMALE; FEMUR HEAD; FEMUR HEAD NECROSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PALLIATIVE THERAPY; PATHOGENESIS; PRIORITY JOURNAL; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; ANTICOAGULANTS; FEMALE; FEMUR HEAD NECROSIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PREDNISOLONE; PROSPECTIVE STUDIES; PULSE THERAPY, DRUG; RISK FACTORS; TIME FACTORS; WARFARIN;

EID: 33745846795     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203306lu2311oa     Document Type: Article

References (16)

1. Rascu A, Manger K, Kraetsch H-G, Kalden JR, Manger B. Osteonecrosis in systemic lupus erythematosus, steroid-induced or a lupus-dependent manifestation? Lupus 1996; 5: 323-327.
2. Gladman DD, Urowitz MB, Chaudhry-Ahluwalia V, Hallet DC, Cook RJ. Predictive factors for symptomatic osteonecrosis in patients with systemic lupus erythematosus. J Rheumatol 2001; 28: 761-765.
3. Mont MA, Glueck CJ, Pacheco IH, Wang P, Hungerford DS, Petri M. Risk factors for osteonecrosis in systemic lupus erythematosus. J Rheumatol 1997; 24: 654-662.
4. Mok CC, Lau CS, Wong RWS. Risk factors for avascular bone necrosis in systemic lupus erythematosus. Br J Rheumatol 1998; 37: 895-900.
5. Assouline-Dayan Y, Chang C, Greenspan A, Shoenfeld Y, Gershwin ME. Pathogenesis and natural history of osteonecrosis. Sem Arthritis Rheum 2002; 32: 94-124.
6. Nagasawa K, Ishii Y, Mayumi T et al. Avascular necrosis of bone in systemic lupus erythematosus: possible role of haematostatic abnormalities. Ann Rheum Dis 1989; 48: 672-676.
7. Cui Q, Wang GJ, Su CC, Balian G. Lovastatin prevents steroid induced adipogenesis and osteonecrosis. Clin Orthop Rel Res 1997; 344: 8-19.
8. Pritchett JW. Statin therapy decreases the risk of osteonecrosis in patients receiving steroids. Clin Orthop Rel Res 2001; 386: 173-178.
9. Tan EM, Cohen AS, Fries JS et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
10. Nagasawa K, Tada Y, Koarada S et al. Very early development of steroid associated osteonecrosis of femoral head in systemic lupus erythematosus: prospective study by MRI. Lupus 2005; 14: 385-390.
11. Dubois EL, Cozen L. Avascular (aseptic) bone necrosis associated with systemic lupus erythematosus. JAMA 1960; 174: 966-984.
12. Oinuma K, Harada Y, Nawata Y et al. Osteonecrosis in patients with systemic lupus erythematosus develops very early after starting high dose corticosteroid treatment. Ann Rheum Dis 2001; 60: 1145-1148.
13. Kalunian KC, Hahn BH, Bassett L. Magnetic resonance imaging identifies early femoral head ischemic necrosis in patients receiving systemic glucocorticoid therapy. J Rheumatol 1989; 16: 959-963.
14. Hauzeur J-P, Sintzoff Jr S, Appelboom T, Maertelaer VD, Bentin J, Pasteels JL. Relationship between magnetic resonance imaging and histologic findings by bone biopsy in nontraumatic osteonecrosis of the femoral head. J Rheumatol 1992; 19: 385-392.
15. Nagasawa K, Tsukamoto H, Tada Y et al. Imaging study on the mode of development and changes in avascular necrosis of the femopral head in systemic lupus erythematosus: Long-term observations. Br J Rheumatol 1994; 33: 343-347.
16. Massardo E, Jacobelli S, Leissner M, Gonzales M, Villarroel L, Rivero S. High dose intravenous methylprednisolone therapy associated with osteonecrosis in patients with systemic lupus erythematosus. Lupus 1992; 1: 401-405.